Insider Buying: Standard BioTools (NASDAQ:LAB) Director Purchases 225,000 Shares of Stock

Standard BioTools Inc. (NASDAQ:LAB) Director Casdin Partners Master Fund, L acquired 225,000 shares of the firm’s stock in a transaction that occurred on Monday, November 17th. The stock was acquired at an average price of $1.22 per share, with a total value of $274,500.00. Following the completion of the transaction, the director directly owned 62,975,000 shares in the company, valued at $76,829,500. This trade represents a 0.36% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Casdin Partners Master Fund, L also recently made the following trade(s):

• On Friday, November 14th, Casdin Partners Master Fund, L bought 250,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.24 per share, for a total transaction of $310,000.00.
• On Thursday, November 13th, Casdin Partners Master Fund, L purchased 450,000 shares of Standard BioTools stock. The stock was bought at an average price of $1.20 per share, with a total value of $540,000.00.
• On Wednesday, November 12th, Casdin Partners Master Fund, L acquired 375,000 shares of Standard BioTools stock. The shares were bought at an average cost of $1.19 per share, with a total value of $446,250.00.
• On Tuesday, November 11th, Casdin Partners Master Fund, L acquired 300,000 shares of Standard BioTools stock. The shares were bought at an average price of $1.20 per share, for a total transaction of $360,000.00.
• On Monday, November 10th, Casdin Partners Master Fund, L acquired 275,000 shares of Standard BioTools stock. The stock was bought at an average cost of $1.17 per share, for a total transaction of $321,750.00.
• On Friday, November 7th, Casdin Partners Master Fund, L bought 225,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.12 per share, with a total value of $252,000.00.
• On Tuesday, September 9th, Casdin Partners Master Fund, L purchased 100,000 shares of Standard BioTools stock. The stock was purchased at an average cost of $1.29 per share, for a total transaction of $129,000.00.
• On Wednesday, September 3rd, Casdin Partners Master Fund, L purchased 250,000 shares of Standard BioTools stock. The stock was purchased at an average price of $1.27 per share, for a total transaction of $317,500.00.
• On Tuesday, August 26th, Casdin Partners Master Fund, L acquired 125,000 shares of Standard BioTools stock. The shares were purchased at an average cost of $1.26 per share, with a total value of $157,500.00.
• On Monday, August 25th, Casdin Partners Master Fund, L acquired 200,000 shares of Standard BioTools stock. The shares were purchased at an average price of $1.24 per share, with a total value of $248,000.00.

Standard BioTools Stock Performance

Standard BioTools stock traded down $0.03 during midday trading on Monday, reaching $1.21. The stock had a trading volume of 1,308,580 shares, compared to its average volume of 1,658,374. The stock has a market capitalization of $465.32 million, a P/E ratio of -3.78 and a beta of 1.25. The firm’s fifty day simple moving average is $1.29 and its 200-day simple moving average is $1.23. Standard BioTools Inc. has a 1-year low of $0.92 and a 1-year high of $2.25.

Institutional Trading of Standard BioTools

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Teacher Retirement System of Texas acquired a new stake in Standard BioTools in the 1st quarter valued at about $35,000. Vanguard Group Inc. increased its position in Standard BioTools by 0.4% during the first quarter. Vanguard Group Inc. now owns 17,225,250 shares of the company’s stock worth $18,603,000 after buying an additional 69,104 shares during the last quarter. XTX Topco Ltd bought a new stake in Standard BioTools in the first quarter valued at approximately $171,000. Pacific Capital Partners Ltd bought a new stake in Standard BioTools in the first quarter valued at approximately $1,701,000. Finally, Rhumbline Advisers lifted its position in shares of Standard BioTools by 11.4% in the first quarter. Rhumbline Advisers now owns 412,761 shares of the company’s stock valued at $446,000 after buying an additional 42,247 shares during the last quarter. 53.74% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently commented on LAB shares. Weiss Ratings reissued a “sell (d-)” rating on shares of Standard BioTools in a research report on Wednesday, October 8th. Wall Street Zen lowered shares of Standard BioTools from a “hold” rating to a “strong sell” rating in a research note on Saturday, November 8th. TD Cowen cut their price target on shares of Standard BioTools from $1.55 to $1.35 and set a “hold” rating on the stock in a research report on Wednesday, November 5th. Finally, Cowen cut Standard BioTools from a “buy” rating to a “hold” rating in a report on Wednesday, August 13th. Three equities research analysts have rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Standard BioTools currently has an average rating of “Reduce” and a consensus target price of $1.35.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.